摘要
利妥昔单抗是一种在B细胞非霍奇金淋巴瘤(B-NHL)中广泛应用的单抗类靶向药物,作用于CD20抗原.其联合化疗显著改善了B细胞淋巴瘤患者的预后.但是仍有部分患者对利妥昔单抗治疗无效或在治疗有效后短期内复发,提示可能存在利妥昔单抗的耐药.利妥昔单抗对B细胞淋巴瘤细胞的杀伤机制主要包括直接诱导凋亡、抗体依赖细胞介导的细胞毒作用(ADCC)、补体依赖细胞毒作用(CDC)等,不同的作用机制可能存在不同的耐药机制,其中哪一种发挥了主要作用尚不明确.文章对利妥昔单抗ADCC作用机制中可能存在的影响疗效的因素进行综述.
Rituximab,a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20,comparing with chemotherapy has significantly improved the treatment outcome of all subgroups of B-cell lymphoma patients.However,not all patients respond to rituximab plus chemotherapy or relapse in a short time after response,which suggests the existence of resistance mechanisms.Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the main mechanisms of rituximab,so any abnormalities in ADCC pathway may affect the efficacy of rituximab.With the widely application of rituximab,its resistance mechanisms are attracting more attention.This review will summarize the factors within ADCC pathway that may affect the antitumor effect of rituximab.
出处
《白血病.淋巴瘤》
CAS
2013年第11期697-700,共4页
Journal of Leukemia & Lymphoma
基金
国家自然科学基金(30973484)